Modernatx, Inc.

Moderna Therapeutics, Inc.

Archemix Corporation

Paul Hatala

Stephane Bancel

Jason P Schrum

Atanu Roy

Antonin De Fougerolles

Sayda Mahgoub Elbashir

Tirtha Chakraborty

Jeff Lynn Ellsworth

Justin Guild

Kenechi Ejebe

Kristy M Wood

Susan Whoriskey

Matthias John

Ron Weiss

John Louis Diener

Markus Kurz

Charles Wilson

Suhaib Siddiqi

Jess Wagner-Whyte

William J Issa

The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified Polynucleotides for the production of biologics and proteins associated with human disease

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Modified polynucleotides for the production of proteins

Modified polynucleotides for the production of secreted proteins

Modified polynucleotides for the production of biologics and proteins associated with human disease

Modified polynucleotides for the production of proteins associated with human disease

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.

Modified polynucleotides for the production of oncology-related proteins and peptides

In vivo production of proteins

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Modified polynucleotides for the production of nuclear proteins

The present disclosure provides methods of increasing the level of a polypeptide of interest in a mammalian subject by administering a polynucleotide having one or more chemical modifications and a Protein:Cytokine ratio of greater than 100.

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

The present invention relates to a compound according to the formula: wherein R, R, R, R, R, R, R, R, Y, Z, n, s, and t are as defined herein. These compounds are useful for methods of solid phase synthesis.

Solid support reagents for synthesis

The invention relates to methods for separating or purifying biopolymer conjugated molecules from unconjugated molecules. In particular, methods are described for purifying a PEGylated protein or oligonucleotide from an unPEGylated protein or oligonucleotide, respectively. The methods are quick and efficient separation methods because they do not require gradient chromatography, fractionation of an eluent or analysis of the eluted fractions. Further, the methods increase yield and purity of the biopolymer conjugated molecule.

Methods of separating biopolymer conjugated molecules from unconjugated molecules

Growing community of inventors

Charlestown, MA, United States of America

Paul Hatala